한글목차

Efgartigimod(ARGX-113)는 IgG를 매개로 한 자가면역질환 치료제로, IgG 항체와 재활용 수용체 FcRn의 자연적 상호작용을 이용하도록 설계되었습니다. 알젠스는 순환하는 질병을 유발하는 자가면역 항체를 분해하는 Efgartigimod를 설계하여 다발성 경화증, 면역성 혈소판 감소증(ITP), 전신성 홍반성 루푸스, 중증 근무력증, 피부 수포성 질환 등 다수의 대형 및 희귀 적응증에 대한 잠재력을 가지고 있습니다.

Efgartigimod는 알젠스만의 ABDEG 기술로 IgG1 항체의 Fc 부분을 변형시켜 FcRn에 대한 친밀도를 일반 IgG 항체보다 높인 것입니다. 그 결과, Efgartigimod는 FcRn 결합에 의한 항체 재활용을 억제하여 자가면역질환의 원인이 되는 IgG 자가항체를 빠르게 고갈시키는 효과를 가져옵니다. Efgartigimod의 개발 연구는 E. Sally Ward 교수(텍사스 대학교 사우스웨스턴 메디컬 스쿨 및 텍사스 A&M 대학교 보건과학센터, 텍사스 A&M 대학교(TAMHSC)의 일부)와의 긴밀한 공동연구를 통해 이루어지고 있습니다. 이 약물은 현재 원발성 ITP 성인 환자를 대상으로 한 임상 3상 시험이 진행 중입니다.

주요 7개국의 ARGX-113 시장에 대해 조사했으며, 시장의 개요와 2024-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 면역성 혈소판 감소증(ITP)에 대한 ARGX-113의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 ARGX-113 시장 평가

• ITP에 대한 ARGX-113의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국에서 ITP에 대한 ARGX-113의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"ARGX-113 Emerging Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about ARGX-113 for immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the ARGX-113 for ITP in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ARGX-113 for ITP. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ARGX-113 market forecast analysis for ITP in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ITP.

Drug Summary:

Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases and was designed to exploit the natural interaction between IgG antibodies and the recycling receptor FcRn Argenx, designed efgartigimod to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications, namely multiple sclerosis, ITP, systemic lupus erythematosus, myasthenia gravis, and skin-blistering diseases.

Efgartigimod is the Fc-portion of an IgG1 antibody modified by the Argenx proprietary ABDEG technology to increase its affinity for FcRn beyond normal IgG antibodies. As a result, efgartigimod blocks antibody recycling through FcRn binding and leads to fast depletion of the autoimmune disease-causing IgG autoantibodies. The development work on efgartigimod is conducted in close collaboration with Prof. E. Sally Ward (University of Texas Southwestern Medical and Texas A&M University Health Science Center, a part of Texas A & M University (TAMHSC)). The drug is currently in Phase III trial for adult patients with primary ITP.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ARGX-113 description, mechanism of action, dosage and administration, research and development activities in immune thrombocytopenic purpura (ITP).
• Elaborated details on ARGX-113 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ARGX-113 research and development activities in ITP across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ARGX-113.
• The report contains forecasted sales of ARGX-113 for ITP till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ITP.
• The report also features the SWOT analysis with analyst views for ARGX-113 in ITP.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARGX-113 Analytical Perspective by DelveInsight

In-depth ARGX-113 Market Assessment

This report provides a detailed market assessment of ARGX-113 for immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

ARGX-113 Clinical Assessment

The report provides the clinical trials information of ARGX-113 for ITP covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for immune thrombocytopenic purpura (ITP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARGX-113 dominance.
• Other emerging products for ITP are expected to give tough market competition to ARGX-113 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARGX-113 in ITP.
• Our in-depth analysis of the forecasted sales data of ARGX-113 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ARGX-113 in ITP.

Key Questions:

• What is the product type, route of administration and mechanism of action of ARGX-113?
• What is the clinical trial status of the study related to ARGX-113 in immune thrombocytopenic purpura (ITP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARGX-113 development?
• What are the key designations that have been granted to ARGX-113 for ITP?
• What is the forecasted market scenario of ARGX-113 for ITP?
• What are the forecasted sales of ARGX-113 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ARGX-113 for ITP?
• Which are the late-stage emerging therapies under development for the treatment of ITP?

Table of Contents

1. Report Introduction

2. ARGX-113 Overview in ITP

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ARGX-113 Market Assessment

• 5.1. Market Outlook of ARGX-113 in ITP
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ARGX-113 in the 7MM for ITP
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ARGX-113 in the United States for ITP
  • 5.3.2. Market Size of ARGX-113 in Germany for ITP
  • 5.3.3. Market Size of ARGX-113 in France for ITP
  • 5.3.4. Market Size of ARGX-113 in Italy for ITP
  • 5.3.5. Market Size of ARGX-113 in Spain for ITP
  • 5.3.6. Market Size of ARGX-113 in the United Kingdom for ITP
  • 5.3.7. Market Size of ARGX-113 in Japan for ITP

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options